Skip to main content
Erschienen in: European Radiology 11/2017

24.04.2017 | Hepatobiliary-Pancreas

Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results

verfasst von: Bachir Taouli, Yujin Hoshida, Suguru Kakite, Xintong Chen, Poh Seng Tan, Xiaochen Sun, Shingo Kihira, Kensuke Kojima, Sara Toffanin, M. Isabel Fiel, Hadassa Hirschfield, Mathilde Wagner, Josep M. Llovet

Erschienen in: European Radiology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

In this preliminary study, we examined whether imaging-based phenotypes are associated with reported predictive gene signatures in hepatocellular carcinoma (HCC).

Methods

Thirty-eight patients (M/F 30/8, mean age 61 years) who underwent pre-operative CT or MR imaging before surgery as well as transcriptome profiling were included in this IRB-approved single-centre retrospective study. Eleven qualitative and four quantitative imaging traits (size, enhancement ratios, wash-out ratio, tumour-to-liver contrast ratios) were assessed by three observers and were correlated with 13 previously reported HCC gene signatures using logistic regression analysis.

Results

Thirty-nine HCC tumours (mean size 5.7 ± 3.2 cm) were assessed. Significant positive associations were observed between certain imaging traits and gene signatures of aggressive HCC phenotype (G3-Boyault, Proliferation-Chiang profiles, CK19-Villanueva, S1/S2-Hoshida) with odds ratios ranging from 4.44–12.73 (P <0.045). Infiltrative pattern at imaging was significantly associated with signatures of microvascular invasion and aggressive phenotype. Significant but weak associations were also observed between each enhancement ratio and tumour-to-liver contrast ratios and certain gene expression profiles.

Conclusions

This preliminary study demonstrates a correlation between phenotypic imaging traits with gene signatures of aggressive HCC, which warrants further prospective validation to establish imaging-based surrogate markers of molecular phenotypes in HCC.

Key points

There are associations between imaging and gene signatures of aggressive hepatocellular carcinoma.
Infiltrative type is associated with gene signatures of microvascular invasion and aggressiveness.
Infiltrative type may be a surrogate marker of microvascular invasion gene signature.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Schena M, Shalon D, Davis RW, Brown PO (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467–470CrossRef Schena M, Shalon D, Davis RW, Brown PO (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467–470CrossRef
2.
Zurück zum Zitat DeRisi JL, Iyer VR, Brown PO (1997) Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 278:680–686CrossRef DeRisi JL, Iyer VR, Brown PO (1997) Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 278:680–686CrossRef
3.
Zurück zum Zitat van’t Veer LJ, Bernards R (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452:564–570CrossRef van’t Veer LJ, Bernards R (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452:564–570CrossRef
4.
Zurück zum Zitat Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM (2010) Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. Semin Liver Dis 30:35–51CrossRef Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM (2010) Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. Semin Liver Dis 30:35–51CrossRef
5.
Zurück zum Zitat Villanueva A, Hoshida Y, Llovet JM (2011) Hepatocellular carcinoma enters the sequencing era. Gastroenterology 141:1943–1945CrossRef Villanueva A, Hoshida Y, Llovet JM (2011) Hepatocellular carcinoma enters the sequencing era. Gastroenterology 141:1943–1945CrossRef
6.
Zurück zum Zitat Villanueva A, Hoshida Y, Battiston C et al (2011) Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140:1501–1512, e1502CrossRef Villanueva A, Hoshida Y, Battiston C et al (2011) Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140:1501–1512, e1502CrossRef
7.
Zurück zum Zitat Villanueva A, Hoshida Y (2011) Depicting the role of TP53 in hepatocellular carcinoma progression. J Hepatol 55:724–725CrossRef Villanueva A, Hoshida Y (2011) Depicting the role of TP53 in hepatocellular carcinoma progression. J Hepatol 55:724–725CrossRef
8.
Zurück zum Zitat Toffanin S, Hoshida Y, Lachenmayer A et al (2011) MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 140:1618–1628, e1616CrossRef Toffanin S, Hoshida Y, Lachenmayer A et al (2011) MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 140:1618–1628, e1616CrossRef
9.
Zurück zum Zitat Minguez B, Hoshida Y, Villanueva A et al (2011) Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 55:1325–1331CrossRef Minguez B, Hoshida Y, Villanueva A et al (2011) Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 55:1325–1331CrossRef
10.
Zurück zum Zitat Villanueva A, Hoshida Y, Toffanin S et al (2010) New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 16:4688–4694CrossRef Villanueva A, Hoshida Y, Toffanin S et al (2010) New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 16:4688–4694CrossRef
11.
Zurück zum Zitat Hoshida Y, Villanueva A, Llovet JM (2009) Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 3:101–103CrossRef Hoshida Y, Villanueva A, Llovet JM (2009) Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 3:101–103CrossRef
12.
Zurück zum Zitat Hoshida Y, Nijman SM, Kobayashi M et al (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69:7385–7392CrossRef Hoshida Y, Nijman SM, Kobayashi M et al (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69:7385–7392CrossRef
13.
Zurück zum Zitat Villanueva A, Chiang DY, Newell P et al (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135:1972–1983, 1983 e1971-1911CrossRef Villanueva A, Chiang DY, Newell P et al (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135:1972–1983, 1983 e1971-1911CrossRef
14.
Zurück zum Zitat Hoshida Y, Villanueva A, Kobayashi M et al (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995–2004CrossRef Hoshida Y, Villanueva A, Kobayashi M et al (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995–2004CrossRef
15.
Zurück zum Zitat Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55–76CrossRef Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55–76CrossRef
16.
Zurück zum Zitat Nault JC, De Reynies A, Villanueva A et al (2013) A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 145:176–187CrossRef Nault JC, De Reynies A, Villanueva A et al (2013) A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 145:176–187CrossRef
17.
Zurück zum Zitat Choi JY, Lee JM, Sirlin CB (2014) CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma: Part II. Extracellular Agents, Hepatobiliary Agents, and Ancillary Imaging Features. Radiology 273:30–50CrossRef Choi JY, Lee JM, Sirlin CB (2014) CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma: Part II. Extracellular Agents, Hepatobiliary Agents, and Ancillary Imaging Features. Radiology 273:30–50CrossRef
18.
Zurück zum Zitat Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 272:635–654CrossRef Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 272:635–654CrossRef
19.
Zurück zum Zitat Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680CrossRef Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680CrossRef
20.
Zurück zum Zitat Kuo MD, Gollub J, Sirlin CB, Ooi C, Chen X (2007) Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol 18:821–831CrossRef Kuo MD, Gollub J, Sirlin CB, Ooi C, Chen X (2007) Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol 18:821–831CrossRef
21.
Zurück zum Zitat Miura T, Ban D, Tanaka S et al (2015) Distinct clinicopathological phenotype of hepatocellular carcinoma with ethoxybenzyl-magnetic resonance imaging hyperintensity: association with gene expression signature. Am J Surg 210:561–569CrossRef Miura T, Ban D, Tanaka S et al (2015) Distinct clinicopathological phenotype of hepatocellular carcinoma with ethoxybenzyl-magnetic resonance imaging hyperintensity: association with gene expression signature. Am J Surg 210:561–569CrossRef
22.
Zurück zum Zitat Chiang DY, Villanueva A, Hoshida Y et al (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68:6779–6788CrossRef Chiang DY, Villanueva A, Hoshida Y et al (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68:6779–6788CrossRef
23.
Zurück zum Zitat Hoshida Y, Moeini A, Alsinet C, Kojima K, Villanueva A (2012) Gene signatures in the management of hepatocellular carcinoma. Semin Oncol 39:473–485CrossRef Hoshida Y, Moeini A, Alsinet C, Kojima K, Villanueva A (2012) Gene signatures in the management of hepatocellular carcinoma. Semin Oncol 39:473–485CrossRef
24.
Zurück zum Zitat Hoshida Y (2010) Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One 5, e15543CrossRef Hoshida Y (2010) Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One 5, e15543CrossRef
25.
Zurück zum Zitat Boyault S, Rickman DS, de Reynies A et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42–52CrossRef Boyault S, Rickman DS, de Reynies A et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42–52CrossRef
26.
Zurück zum Zitat Woo HG, Lee JH, Yoon JH et al (2010) Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 70:3034–3041CrossRef Woo HG, Lee JH, Yoon JH et al (2010) Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 70:3034–3041CrossRef
27.
Zurück zum Zitat Andersen JB, Loi R, Perra A et al (2010) Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology 51:1401–1409CrossRef Andersen JB, Loi R, Perra A et al (2010) Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology 51:1401–1409CrossRef
28.
Zurück zum Zitat Coulouarn C, Factor VM, Thorgeirsson SS (2008) Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47:2059–2067CrossRef Coulouarn C, Factor VM, Thorgeirsson SS (2008) Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47:2059–2067CrossRef
29.
Zurück zum Zitat Cairo S, Armengol C, De Reynies A et al (2008) Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 14:471–484CrossRef Cairo S, Armengol C, De Reynies A et al (2008) Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 14:471–484CrossRef
30.
Zurück zum Zitat Yamashita T, Forgues M, Wang W et al (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68:1451–1461CrossRef Yamashita T, Forgues M, Wang W et al (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68:1451–1461CrossRef
31.
Zurück zum Zitat Franssen B, Alshebeeb K, Tabrizian P et al (2014) Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg 260:650–656, discussion 656-658CrossRef Franssen B, Alshebeeb K, Tabrizian P et al (2014) Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg 260:650–656, discussion 656-658CrossRef
32.
Zurück zum Zitat Lee JS, Chu IS, Heo J et al (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40:667–676CrossRef Lee JS, Chu IS, Heo J et al (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40:667–676CrossRef
33.
Zurück zum Zitat Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582–1595CrossRef Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582–1595CrossRef
34.
Zurück zum Zitat Woo HG, Park ES, Cheon JH et al (2008) Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 14:2056–2064CrossRef Woo HG, Park ES, Cheon JH et al (2008) Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 14:2056–2064CrossRef
35.
Zurück zum Zitat Bruix J, Sherman M, American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRef Bruix J, Sherman M, American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRef
36.
Zurück zum Zitat Yopp AC, Mokdad A, Zhu H et al (2015) Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma. Ann Surg Oncol 22(Suppl 3):1075–1082CrossRef Yopp AC, Mokdad A, Zhu H et al (2015) Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma. Ann Surg Oncol 22(Suppl 3):1075–1082CrossRef
37.
Zurück zum Zitat Mehta N, Fidelman N, Sarkar M, Yao FY (2013) Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol 11:572–578CrossRef Mehta N, Fidelman N, Sarkar M, Yao FY (2013) Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol 11:572–578CrossRef
38.
Zurück zum Zitat Renzulli M, Brocchi S, Cucchetti A et al (2015) Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma? Radiology 279:432–442CrossRef Renzulli M, Brocchi S, Cucchetti A et al (2015) Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma? Radiology 279:432–442CrossRef
39.
Zurück zum Zitat Banerjee S, Wang DS, Kim HJ et al (2015) A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology 62:792–800CrossRef Banerjee S, Wang DS, Kim HJ et al (2015) A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology 62:792–800CrossRef
40.
Zurück zum Zitat Mazzaferro V, Llovet JM, Miceli R et al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10:35–43CrossRef Mazzaferro V, Llovet JM, Miceli R et al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10:35–43CrossRef
41.
Zurück zum Zitat Goossens N, Sun X, Hoshida Y (2015) Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol 2:371–379CrossRef Goossens N, Sun X, Hoshida Y (2015) Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol 2:371–379CrossRef
42.
Zurück zum Zitat Liu PH, Hsu CY, Hsia CY et al (2016) Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol 64:601–608CrossRef Liu PH, Hsu CY, Hsia CY et al (2016) Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol 64:601–608CrossRef
43.
Zurück zum Zitat van den Bos IC, Hussain SM, Dwarkasing RS et al (2007) MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging 26:1548–1555CrossRef van den Bos IC, Hussain SM, Dwarkasing RS et al (2007) MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging 26:1548–1555CrossRef
44.
Zurück zum Zitat Ronzoni A, Artioli D, Scardina R et al (2007) Role of MDCT in the diagnosis of hepatocellular carcinoma in patients with cirrhosis undergoing orthotopic liver transplantation. AJR Am J Roentgenol 189:792–798CrossRef Ronzoni A, Artioli D, Scardina R et al (2007) Role of MDCT in the diagnosis of hepatocellular carcinoma in patients with cirrhosis undergoing orthotopic liver transplantation. AJR Am J Roentgenol 189:792–798CrossRef
45.
Zurück zum Zitat Witjes CD, Willemssen FE, Verheij J et al (2012) Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. J Magn Reson Imaging 36:641–647CrossRef Witjes CD, Willemssen FE, Verheij J et al (2012) Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. J Magn Reson Imaging 36:641–647CrossRef
46.
Zurück zum Zitat Enomoto S, Tamai H, Shingaki N et al (2011) Assessment of hepatocellular carcinomas using conventional magnetic resonance imaging correlated with histological differentiation and a serum marker of poor prognosis. Hepatol Int 5:730–737CrossRef Enomoto S, Tamai H, Shingaki N et al (2011) Assessment of hepatocellular carcinomas using conventional magnetic resonance imaging correlated with histological differentiation and a serum marker of poor prognosis. Hepatol Int 5:730–737CrossRef
47.
Zurück zum Zitat Taouli B, Johnson RS, Hajdu CH et al (2013) Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI. AJR Am J Roentgenol 201:795–800CrossRef Taouli B, Johnson RS, Hajdu CH et al (2013) Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI. AJR Am J Roentgenol 201:795–800CrossRef
48.
Zurück zum Zitat Taouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254:47–66CrossRef Taouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254:47–66CrossRef
49.
Zurück zum Zitat Bane O, Besa C, Wagner M et al (2016) Feasibility and reproducibility of BOLD and TOLD measurements in the liver with oxygen and carbogen gas challenge in healthy volunteers and patients with hepatocellular carcinoma. J Magn Reson Imaging 43:866–876CrossRef Bane O, Besa C, Wagner M et al (2016) Feasibility and reproducibility of BOLD and TOLD measurements in the liver with oxygen and carbogen gas challenge in healthy volunteers and patients with hepatocellular carcinoma. J Magn Reson Imaging 43:866–876CrossRef
50.
Zurück zum Zitat Hectors SJ, Wagner M, Bane O, et al (2017) Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Sci Rep (in press) Hectors SJ, Wagner M, Bane O, et al (2017) Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Sci Rep (in press)
Metadaten
Titel
Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results
verfasst von
Bachir Taouli
Yujin Hoshida
Suguru Kakite
Xintong Chen
Poh Seng Tan
Xiaochen Sun
Shingo Kihira
Kensuke Kojima
Sara Toffanin
M. Isabel Fiel
Hadassa Hirschfield
Mathilde Wagner
Josep M. Llovet
Publikationsdatum
24.04.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 11/2017
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-4844-6

Weitere Artikel der Ausgabe 11/2017

European Radiology 11/2017 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.